| 陈慧昱,柯 丽,王 赟,刘鑫佳,杨 光.参麦注射液联合吉西他滨和顺铂对晚期NSCLC患者肿瘤标志物、
T淋巴细胞亚群和血清凋亡分子的影响[J].现代生物医学进展英文版,2024,(20):3984-3986. |
| 参麦注射液联合吉西他滨和顺铂对晚期NSCLC患者肿瘤标志物、
T淋巴细胞亚群和血清凋亡分子的影响 |
| Effects of Shenmai Injection Combined with Gemcitabineand Cisplatin on Tumor Markers, T Lymphocyte Subsetsand Serum Apoptotic Molecules in Patients with Advanced NSCLC |
| Received:May 16, 2024 Revised:June 10, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.20.051 |
| 中文关键词: 参麦注射液 吉西他滨 顺铂 晚期非小细胞肺癌 肿瘤标志物 T淋巴细胞亚群 凋亡分子 |
| 英文关键词: Shenmai Injection Gemcitabine Cisplatin Advanced non-small cell lung cancer Tumor markers T lymphocyte subsets Apoptotic molecules |
| 基金项目:陕西省重点研发计划项目（2019SF-085） |
|
| Hits: 5 |
| Download times: 4 |
| 中文摘要: |
| 摘要 目的：探讨参麦注射液联合吉西他滨和顺铂对晚期非小细胞肺癌（NSCLC）患者肿瘤标志物、T淋巴细胞亚群和血清凋亡分子的影响。方法：将在2020年3月~2022年12月期间我院收治的118例晚期NSCLC患者以随机数字表法分为联合组（n=59，参麦注射液联合吉西他滨和顺铂治疗）和对照组（n=59，吉西他滨和顺铂治疗）。对比两组肿瘤标志物水平、T淋巴细胞亚群、凋亡分子。结果：与对照组相比，联合组治疗后细胞角蛋白19片段（CYFRA21-1）、癌胚抗原（CEA）、鳞状细胞癌相关抗原（SCC）、糖类抗原125（CA125）、B淋巴细胞瘤（Bcl-2）、生存素（Survivin）、CD8+更低，Bcl-2相关X蛋白（Bax）、CD3+、CD4+、CD4+/CD8+更高（P<0.05）。结论：参麦注射液联合吉西他滨和顺铂治疗晚期NSCLC患者，能够降低肿瘤标志物水平，减轻患者免疫抑制，调节血清凋亡分子水平。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of shenmai injection combined with gemcitabine and cisplatin on tumor markers, T lymphocyte subsets and serum apoptotic molecules in patients with advanced non-small cell lung cancer (NSCLC). Methods: 118 patients with advanced NSCLC who were admitted to our hospital from March 2020 to December 2022 were divided into combined group (n=59, treated with shenmai injection combined with gemcitabine and cisplatin) and control group (n=59, treated with gemcitabine and cisplatin ) by random number table method. The tumor marker level, T lymphocyte subsets and apoptotic molecules were compared between two groups. Results: Compared with control group, cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), sqamous cell carcinoma antigen (SCC), carbohydrate antigen 125 (CA125), B-cell lymphoma (Bcl-2), Survivin (Survivin), CD8+ were lower in combined group after treatment, and Bcl-2-related X protein (Bax) and CD3+, CD4+, CD4+/CD8+ were higher (P<0.05). Conclusion: Shenmai injection combined with gemcitabine and cisplatin for the treatment of advanced NSCLC Patients, which can reduce tumor markers level, reduce the immunosuppression of patients, regulate serum apoptotic molecules level. |
|
View Full Text
View/Add Comment Download reader |
| Close |
